EnVVeno presents positive 11-month topline efficacy data for VenoValve in SAVVE U.S. trial.

enVVeno Medical Corporation presents positive 11-month topline efficacy data from its SAVVE U.S. pivotal trial for VenoValve, showing an overall 8.46 average Revised Venous Clinical Severity Score (rVCSS) improvement per patient. 72% of study patients showed clinical meaningful benefit, while 94% showed clinical improvement at a weighted average of 11 months post-surgery. The company is on track to file for VenoValve FDA approval in Q4 2024.

April 24, 2024
4 Articles